Toft Group Completes Vice President of Sales Search for OncoCyte Corporation (NYSE: OCX) in Alameda, CA

OncoCyte Corporation (NYSE: OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that Michael G. Vicari has been appointed to the newly created position of Vice President of Sales. Mr. Vicari will report directly to William Annett, President and Chief Executive Officer. He will be responsible for the development and successful implementation of the Company’s domestic and international sales strategies, with an initial focus on the expected fourth quarter U.S. launch of DetermaVu™, the Company’s liquid biopsy lung cancer diagnostic.

“Our commitment to building out and executing our sales strategy reflects our plan to make DetermaVu™ the first test of its kind to reach the medical market, and we expect the U.S. commercial launch in the fourth quarter of this year,” said Mr. Annett. “Michael’s experience building and leading sales organizations at major diagnostic companies, and proven success in driving significant revenues, will be invaluable as we launch DetermaVu™ and drive adoption by physicians.”

Robin Toft, President and CEO of Toft Group said: “We are thrilled to have worked with the senior leadership of OncoCyte, and congratulate Mike on his new role. We have every confidence that he will make an exceptional contribution to the company’s continued success.”

Mr. Vicari brings 35 years of successful sales and marketing leadership within the healthcare industry, including the launch of several important diagnostic products. Before joining OncoCyte, he was with Eurofins Scientific as Vice President of Sales & Marketing for the Clinical Diagnostics business where he established two separate sales and marketing organizations for EGL (rare genetic testing) & NTD (prenatal testing) while leading all commercial functions.

Prior to Eurofins, he was Vice President of Sales for Sequenom, Inc., leading sales and strategy for nearly five years.  While at Sequenom, Mr. Vicari led the successful launch of their revolutionary women’s health test, NIPT MaterniT21, and launching of the Universal Carrier Screen, NIPT VisibiliT, and drove overall Sequenom sales from $0 to over $150 million per year. Prior to Sequenom, Mr. Vicari was the Vice President of Sales and Marketing for Oncology/HIV at Monogram Biosciences before it was acquired by LabCorp. In this role, he led sales, marketing and clinical training and also managed the launch of HerMark for breast cancer. Mr. Vicari has served in senior commercial leadership roles at Genentech, Corixa Oncology, and MedImmune.

“OncoCyte is approaching an exciting inflection point as it prepares for the anticipated launch of DetermaVu™, and I’m thrilled that I will be spearheading the launch and commercial rollout of this important product,” commented Mr. Vicari. “DetermaVu™ has the potential to change the paradigm in lung cancer diagnostics, thereby saving lives and lowering treatment costs for millions of patients by helping to identify lung cancer at an earlier, more treatable stage, and reducing the need for potentially dangerous and expensive invasive biopsies. I look forward to working tirelessly with the entire team to make DetermaVu™ a commercial success.”

About Toft Group Executive Search

Toft Group Executive Search is “Changing the Future, One Relationship at a Time” and we take pride in the fact that our work helps our clients accelerate getting novel products to market. We are a global retained executive search firm that is 100% dedicated to life sciences & healthcare industries.  Our customers include biotech, pharmaceutical, medical device, digital health, and diagnostic companies. With offices in San Francisco, San Diego, and Boston, we assist a wide range of local, national and international companies – from venture backed start-ups to Fortune 500 corporations.

About OncoCyte Corporation

OncoCyte is focused on the development and commercialization of novel, non-invasive blood and urine (“liquid biopsy”) diagnostic tests for the early detection of cancer to improve health outcomes through earlier diagnoses, to reduce the cost of care through the avoidance of more costly diagnostic procedures, including invasive biopsy and cystoscopic procedures, and to improve the quality of life for cancer patients. While current biopsy tests use invasive surgical procedures to provide tissue samples in order to determine if a tumor is benign or malignant, OncoCyte is developing a next generation of diagnostic tests that will be based on liquid biopsies using blood or urine samples. OncoCyte’s pipeline products are intended to be confirmatory diagnostics for detecting lung, breast and bladder cancer. OncoCyte’s diagnostic tests are being developed using proprietary sets of genetic and protein markers that differentially express in specific types of cancer.

Robin Toft featured in STAT: A Biotech Recruiter’s Advice to Women: You Don’t Have to Be Perfect

Too often, women hesitate to pursue a new opportunity or position simply because they don’t feel they’re qualified. Where men confidently apply for a role when they only meet 60% of the job qualifications, women tend to only apply if they meet 100%.

Robin Toft shares her thoughts on the need for women to put aside the “not good enough” mentality. Why? Because there’s no better time for them to land their dream job in biotech than right now.

View Robin’s interview in STAT

Robin Toft Interviewed by WealthChoice: Aiming for the C-Suite? 4 Resources You Need

Your career is what you make it, but developing key relationships can make all the difference in how far you’ll go.

Robin Toft has advised many men and women on their career paths to the C-Suite. While they have all had extensive experience and an impressive resume, additional resources and relationships have played a significant role in their success.

Robin’s interview with WealthChoice outlines these 4 key areas that should be part of your ongoing career development to land a seat at the executive table.

Read Robin’s interview with WealthChoice

Toft Group Completes Executive Search for Retrophin, Inc., (NASDAQ: RTRX) in San Diego, CA

Executive search firm Toft Group has placed Dr. Forrest Fuller as Executive Director, Business Development at Retrophin, Inc., in San Diego, CA. He offers 25+ years of early stage biotechnology experience spanning business development, licenses, M&A transactions as well as developing alliances and partnerships. He formerly served with Organovo as their VP of Business Development, where he managed opportunities to leverage Organovo’s 3D Bioprinting technology for value inflection through spinouts, acquisitions and strategic drug discovery alliances. He earned a PhD in Biochemistry and Molecular Biology from Harvard University.

About Retrophin, Inc.

Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company’s approach centers on its pipeline featuring late-stage assets targeting rare diseases with significant unmet medical needs, including fosmetpantotenate for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood, and sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease. Research exploring additional rare diseases is also underway. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Thiola®, Cholbam® and Chenodal®.

Robin Toft in Xconomy: An Insider’s Guide to Bridging the Biotech Gender Gap

As an executive recruiter who has spent an extensive career placing top-level candidates in life sciences and healthcare positions, Robin Toft is the first to acknowledge the industry’s gender gap.

However the job market is shifting. Finding and retaining talent is one of the biggest challenges for companies, and the pressure is only increasing.

Robin reveals why, for women, the change means there is no better time to land an executive role in biotech.

Read Robin’s Article on Xconomy

 

Vote for Robin as SXSW 2018 Speaker!

Robin has been accepted by SXSW 2018 Panelist Picker as a potential speaker on bridging the gender gap, but she needs your vote to get slated!

Click here to watch her video and cast your vote 

Toft Group Completes Senior Vice President of R&D Search for Dovetail Genomics in Santa Cruz, CA

Dovetail Genomics™ LLC, the industry leader in the use of proximity ligation and advanced informatics for genomic solutions, has appointed Dr. Ramesh Ramakrishnan Senior Vice President of Research and Development. Prior to joining Dovetail, Dr. Ramakrishnan was Executive Vice President of Research and Development at Fluidigm Corp., where he managed the development of single cell genomic and proteomic tools, as well as bulk genomic analysis.

“We are thrilled to welcome Ramesh to the Dovetail team,” said Todd Dickinson, CEO of Dovetail Genomics. “His deep experience in the development and commercialization of genomic products and solutions represents an important addition to the management team as we continue expanding our portfolio. Just as important, he will be responsible for identifying new opportunities to leverage our core expertise, driving the development of exciting new applications in genomics for our customers.”

Robin Toft, President and CEO of Toft Group said: “Dovetail is a forward-thinking organization with an incredibly passionate leadership team. Ramesh will add great value to the organization, and will be a strong contributor to the continued growth of the company.”

Dr. Ramakrishnan brings to Dovetail more than 25 years experience in biotech and clinical research, and in commercialization of genomic solutions. He holds a PhD in Zoology from Georgetown University and the University of Poona, India, which he earned through the Fulbright Scholarship Program. Prior to his tenure at Fluidigm, Dr. Ramakrishnan worked at Nanosphere and Motorola Life Sciences in assay and array development.Robin Toft, President and CEO of Toft Group said: “GeneCentric is a forward-thinking organization with an incredibly passionate leadership team. Walter will add great value to the organization, and will be a strong contributor to the continued growth of the company.”

About Toft Group Executive Search

Toft Group Executive Search is “Changing the Future, One Relationship at a Time” and we take pride in the fact that our work helps our clients accelerate getting novel products to market. We are a global retained executive search firm that is 100% dedicated to life sciences & healthcare industries.  Our customers include biotech, pharmaceutical, medical device, digital health, and diagnostic companies. With offices in San Francisco, San Diego, and Boston, we assist a wide range of local, national and international companies – from venture backed start-ups to Fortune 500 corporations.

About Dovetail Genomics

Dovetail Genomics LLC is transforming genomics by making long-range information readily accessible to all. The company enables researchers and clinicians to solve complex problems involving de novo assembly, structural variation, microbiome analysis, cancer research, phasing analysis and more by providing them a more comprehensive view of the genome. Its proprietary in vitro proximity ligation approach and assembly algorithms simplify genomic discovery by integrating the highest quality long-range genomic information with next-gen sequencing output. Dovetail is based in Santa Cruz, California.

Toft Group Completes Executive Search for Anatrace, Inc., in Maumee, OH

Executive search firm Toft Group has placed Mr. Mike Irwin as Vice President of Sales at Anatrace, Inc., in Maumee, OH.  Previously, he served with Raindance Technologies as Director of Sales Americas where he drove sales of their RainDrop Plus™ Digital PCR and ThunderStorm® Next-Generation Sequencing Target Enrichment Systems. He earned an MBA from Pepperdine University.

About Anatrace, Inc.

Research facilities, academic institutions, and industrial customers worldwide have trusted Anatrace for high-purity detergents, lipids, customs, and, of course, higher standards since the late 1980s. Well regarded as top performers for membrane protein structural biology, Anatrace products are chosen for their uniquely pure molecules – and the exacting chemistry behind them.

Toft Group Completes Executive Search for Cell Medica, Ltd. in Houston, TX

Executive search firm Toft Group has placed Dr. Luis Borges as Chief Scientific Officer at Cell Medica, Ltd. in Houston, TX. Dr. Borges most recently served at Five Prime Therapeutics as the Senior Vice President, Research, where he assisted in rebuilding the company’s pipeline and re-focusing efforts in cancer immunotherapy. For 12 years prior, he held multiple roles at Amgen, Inc., where his work focused on the development of new immunotherapy approaches to engage different immune cell subsets to eliminate malignant cells. Dr. Borges earned his BS from the University of Lisbon, and his PhD in Pathology for the University of Washington.

About Cell Medica

Cell Medica is committed to transforming patients’ lives through developing the significant therapeutic potential of cellular immunotherapy for the treatment of cancer. In collaboration with our strategic partners, Cell Medica is developing a range of products using three proprietary technology platforms including activated T cells, chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs). Our lead product is CMD-003 is being tested in an international Phase II trial for the treatment of cancers associated with the oncogenic Epstein Barr virus. We are working with the Baylor College of Medicine and the University of North Carolina to develop next generation CAR- modified NKT cells including an off-the-shelf product. In the field of engineered TCRs, we are collaborating with University College London to develop the Dominant TCR technology platform. Cell Medica is headquartered in London with subsidiaries in Zurich and Houston.

Toft Group Completes Executive Search for bioTheranostics in San Diego, CA

Executive search firm Toft Group has placed Ms. Debra Hadley as Vice President of Laboratory Operations at bioTheranostics in San Diego, CA. She offers 30+ years of laboratory operations management, most recently serving as VP of Operations Excellence and Head of Laboratory Operations for Genoptix. She earned an MBA from the University of Phoenix.

About bioTheranostics

bioTheranostics, part of the worldwide bioMérieux group, discovers, develops, and commercializes molecular-based diagnostic, prognostic, and predictive tests that support physicians in the treatment of patients with cancer. The company operates a CLIA-certified, CAP-accredited diagnostic service laboratory in San Diego, CA.

Toft Group Completes Executive Search for Zenith Epigenetics, Ltd. in Calgary, Alberta, Canada

Executive search firm Toft Group has placed Dr. Edward van der Horst as Vice President, Discovery Biology & Pre-Clinical Development at Zenith Epigenetics, Ltd., in Calgary, Alberta, Canada. Dr. van der Horst brings 15 years of experience developing monoclonal antibody therapeutics, target discovery, selection and validation. He previously served at Igenica Biotherapeutics as Senior Director of Preclinical Drug Development. Previous, Dr. van der Horst’s contributions and discoveries at OncoMed Pharmaceuticals as a Senior Scientist have led to the development and clinical evaluation of anti-DLL4 and anti-NOTCH2/3 antibodies, the first clinical stage anti-HER3 antibody at U3 Pharma GmbH. Dr. van der Horst earned his MSc in Chemistry from Ludwig-Maximillians University and his PhD in Biochemistry from Max-Planck Institute for Biochemistry, both located in Munich, Germany.

About Zenith Epigenetics, Ltd.

Zenith Capital Corp. is a biotechnology investment company. Zenith Epigenetics Ltd., a wholly-owned subsidiary of Zenith Capital Corp., is a clinical stage biotechnology company focused on the discovery and development of novel therapeutics. Zenith Epigenetics Ltd.’s bromodomain (BET) inhibitors are being advanced in several oncology indications and have the potential to impact multiple additional diseases as well. The lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (mCRPC).